-melanoma skin cancer (NMSC) in the United States costs Medicare more than $400 million per year. 5 , 6 Furthermore, the incidence of this common malignancy is rising rapidly. 1 , 7 – 13 BCCs are at least 2 times more common than squamous cell carcinomas (SCCs
Search Results
Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Susan A. Higgins, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, Kishwer S. Nehal, Paul Nghiem, Elise A. Olsen, Chrysalyne D. Schmults, Aleksandar Sekulic, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Sandra L. Wong, John A. Zic, Karin G. Hoffmann, and Anita Engh
Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman
N on-melanoma skin cancers (NMSCs), characterized by malignant growth of the epithelial layer or external surface of the skin, are the most prevalent form of skin cancer in the United States. 1 Since the 1960s, the incidence of NMSC has increased
Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic
Overview Basal and squamous cell skin cancers, collectively known as non-melanoma skin cancers (NMSC), are the most common skin cancers. 1 , 2 More than 1 million cases of NMSC are estimated to be diagnosed each year in the United States and
Roy H. Decker and Lynn D. Wilson
-cell carcinoma of the skin . Lancet Oncol 2004 ; 5 : 593 – 599 . 16. Veness MJ Perera L McCourt J . Merkel cell carcinoma: improved outcome with adjuvant radiotherapy . Aust N Z J Surg 2005 ; 75 : 275 – 281 . 17. Veness MJ . Merkel
Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
A wide range of approaches exist for treating aggressive nonmelanoma skin cancers, including surgery, radiation therapy (RT), cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. Selecting an appropriate therapeutic approach
Shoko Mori, Cristian Navarrete-Dechent, Tatyana A. Petukhova, Erica H. Lee, Anthony M. Rossi, Michael A. Postow, Lara A. Dunn, Benjamin R. Roman, Vivian T. Yin, Daniel G. Coit, Travis J. Hollmann, Klaus J. Busam, Kishwer S. Nehal, and Christopher A. Barker
Skin cancer is the most common form of cancer in the United States. The incidence of nonmelanoma skin cancer (NMSC), such as basal cell and squamous cell carcinomas, has increased from an estimated 3.5 million cases in 2006 to 5.4 million cases in
Thomas Olencki
We need to change direction on therapies for unresectable or metastatic nonmelanoma skin cancers, pronounced Thomas Olencki, DO, Clinical Professor of Internal Medicine and Vice Chair of the Division of Medical Oncology, The Ohio State University
Sari M. Fien and Allan R. Oseroff
-melanoma skin cancer cells . Br J Dermatol 2006 ; 154 ( suppl 1 ): 16 – 21 . 9. Oseroff AR Shieh S Frawley NP . Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5
Marcy Neuburg
transplantation . Transplant Proc 1993 ; 25 : 1383 – 1384 . 5. Bouwes Bavinck JN Hardie DR Green A . The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study . Transplantation 1996 ; 61 : 715 – 721
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022
Featured Updates to the NCCN Guidelines
Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Brian C. Baumann, Jeremy Bordeaux, Pei-Ling Chen, Robert Chin, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Roy C. Grekin, Kelly Harms, Alan L. Ho, Ashley Holder, John Nicholas Lukens, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Soo Park, Tejesh Patel, Igor Puzanov, Jeffrey Scott, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, William Stebbins, Valencia Thomas, Yaohui G. Xu, Beth McCullough, Mary A. Dwyer, and Mai Q. Nguyen
this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Squamous Cell Skin Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for
